These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19381049)

  • 1. [Significance of urinary uracil measurement following administration of DPD inhibitory fluoropyrimidine(DIF)products].
    Horiuchi T; Shono Y; Miyabe T; Nakajima Y; Akiyama I; Uchida K; Fujita Y; Hasegawa K; Tabuse K
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):683-6. PubMed ID: 19381049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
    Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer].
    Morimoto S; Tsuji T; Shono Y; Akiyama I; Fujita Y; Hasegawa K; Tabuse K
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):947-50. PubMed ID: 18633222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
    Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
    Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
    Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
    Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative].
    Morimoto S; Mishima H; Tsujinaka T; Kawato N; Shono Y; Tsuji T; Tabuse K; Nakata I; Saito M; Uenaka K
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):89-94. PubMed ID: 12557710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
    Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
    Drug Metab Dispos; 2005 Mar; 33(3):381-7. PubMed ID: 15616154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
    Kai K; Endo Y; Yoshida K; Morikawa T; Nobuhisa T; Watanabe T; Matsumoto Y; Yamada T; Doi Y; Nakashima A; Nagahiro W; Ishizuka S; Sato S; Nakashima A; Nabeyama A
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Yen-Revollo JL; Goldberg RM; McLeod HL
    Clin Cancer Res; 2008 Jan; 14(1):8-13. PubMed ID: 18172246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria.
    Hayashi K; Kidouchi K; Sumi S; Mizokami M; Orito E; Kumada K; Ueda R; Wada Y
    Clin Cancer Res; 1996 Dec; 2(12):1937-41. PubMed ID: 9816152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2008 Jan; 18(1):25-35. PubMed ID: 18216719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of intratumoral TS levels and DPD activity in breast cancer].
    Miyashita M; Yoshimura H; Hatta K; Tachibana S; Kubota M; Takahashi H; Yamazaki Y; Maeda K; Okita Y; Takao S
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):407-11. PubMed ID: 19295264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio.
    Sumi S; Kidouchi K; Hayashi K; Imaeda M; Asai M; Wada Y
    Adv Exp Med Biol; 1998; 431():191-5. PubMed ID: 9598057
    [No Abstract]   [Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.
    Ito S; Kawamura T; Inada M; Inoue Y; Hirao Y; Koga T; Kunizaki J; Shimizu T; Sato H
    Br J Clin Pharmacol; 2005 Dec; 60(6):584-93. PubMed ID: 16305582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A neonate with recurrent vomiting and generalized hypotonia diagnosed with a deficiency of dihydropyrimidine dehydrogenase.
    Brussel W; van Kuilenburg AB; Janssens PM
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1099-102. PubMed ID: 17065071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
    Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y
    Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.